Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Ischemic Heart Disease

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 121 articles:
HTML format
Text format



Single Articles


    August 2019
  1. NASLUND U, Lundgren A, Vanoli D, Norberg M, et al
    Is intima-media thickness a predictor for cardiovascular risk? - Authors' reply.
    Lancet. 2019;394:381.
    PubMed     Text format    


  2. GONZALEZ-CANTERO A, Gonzalez-Cantero J, Sanchez-Moya AI, Rodriguez-Padial L, et al
    Is intima-media thickness a predictor for cardiovascular risk?
    Lancet. 2019;394:380-381.
    PubMed     Text format    


    July 2019
  3. HERRETT E, Gadd S, Jackson R, Bhaskaran K, et al
    Eligibility and subsequent burden of cardiovascular disease of four strategies for blood pressure-lowering treatment: a retrospective cohort study.
    Lancet. 2019 Jul 25. pii: S0140-6736(19)31359.
    PubMed     Text format     Abstract available


    June 2019
  4. BARNETT R
    Acute myocardial infarction.
    Lancet. 2019;393:2580.
    PubMed     Text format    


  5. TIJSSEN RYG, de Winter RJ, Wykrzykowska JJ
    ABSORB IV: will the low rate of scaffold thrombosis persist?
    Lancet. 2019;393:2392.
    PubMed     Text format    


  6. STONE GW, Ellis SG, Kereiakes DJ
    ABSORB IV: will the low rate of scaffold thrombosis persist? - Authors' reply.
    Lancet. 2019;393:2392-2393.
    PubMed     Text format    


  7. RISSANEN TT, Uskela S, Eranen J, Mantyla P, et al
    Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial.
    Lancet. 2019 Jun 13. pii: S0140-6736(19)31126.
    PubMed     Text format     Abstract available


  8. GERSTEIN HC, Colhoun HM, Dagenais GR, Diaz R, et al
    Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31149.
    PubMed     Text format     Abstract available


  9. OIKONOMOU EK, Antoniades C
    Detection of coronary inflammation - Authors' reply.
    Lancet. 2019;393:2199-2200.
    PubMed     Text format    


    May 2019
  10. RABER I, McCarthy CP, Vaduganathan M, Bhatt DL, et al
    The rise and fall of aspirin in the primary prevention of cardiovascular disease.
    Lancet. 2019;393:2155-2167.
    PubMed     Text format     Abstract available


  11. FUDIM M, Ali-Ahmed F, Patel MR, Sobotka PA, et al
    Sham trials: benefits and risks for cardiovascular research and patients.
    Lancet. 2019;393:2104-2106.
    PubMed     Text format    


  12. JEGER RV, Kaiser C, Gilgen N, Coslovsky M, et al
    Drug-coated balloons: room for development of BASKET-SMALL 2 - Authors' reply.
    Lancet. 2019;393:1934-1935.
    PubMed     Text format    


  13. SAJADIEH A, Kumarathurai P, Jeppesen JL
    Drug-coated balloons: room for development of BASKET-SMALL 2.
    Lancet. 2019;393:1934.
    PubMed     Text format    


  14. ALFONSO F, Guimaraes MG, Rivero F, Cuesta J, et al
    Drug-coated balloons: room for development of BASKET-SMALL 2.
    Lancet. 2019;393:1933-1934.
    PubMed     Text format    


  15. SHAH R, Khan B
    The MATRIX trial.
    Lancet. 2019;393:1803.
    PubMed     Text format    


  16. MEYER TM, Hollenbeck M, Kielstein JT
    The MATRIX trial.
    Lancet. 2019;393:1802-1803.
    PubMed     Text format    


  17. PICCOLO R, Bonaa KH, Efthimiou O, Varenne O, et al
    Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials.
    Lancet. 2019 May 2. pii: S0140-6736(19)30474.
    PubMed     Text format     Abstract available


  18. JENSEN LO, Christiansen EH
    Are drug-eluting stents safer than bare-metal stents?
    Lancet. 2019 May 2. pii: S0140-6736(19)31000.
    PubMed     Text format    


    April 2019
  19. MCCALL B
    Alemtuzumab to be restricted pending review, says EMA.
    Lancet. 2019;393:1683.
    PubMed     Text format    


  20. MILLWOOD IY, Walters RG, Mei XW, Guo Y, et al
    Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China.
    Lancet. 2019 Apr 4. pii: S0140-6736(18)31772.
    PubMed     Text format     Abstract available


    March 2019
  21. THE LANCET EDITORS
    Retraction-Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial.
    Lancet. 2019;393:1084.
    PubMed     Text format    


  22. COSTACOU T, Guo J, Miller RG, Orchard TJ, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:985.
    PubMed     Text format    


  23. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes - Authors' reply.
    Lancet. 2019;393:985-986.
    PubMed     Text format    


  24. SNAITH JR, Holmes-Walker DJ, Girgis CM, Greenfield JR, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:984-985.
    PubMed     Text format    


  25. BAX JJ, Di Carli M, Narula J, Delgado V, et al
    Multimodality imaging in ischaemic heart failure.
    Lancet. 2019;393:1056-1070.
    PubMed     Text format     Abstract available


  26. MCCRINDLE BW, Rowley AH
    Improving coronary artery outcomes for children with Kawasaki disease.
    Lancet. 2019 Mar 7. pii: S0140-6736(18)33133.
    PubMed     Text format    


  27. HAMADA H, Suzuki H, Onouchi Y, Ebata R, et al
    Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised
    Lancet. 2019 Mar 7. pii: S0140-6736(18)32003.
    PubMed     Text format     Abstract available


    February 2019
  28. KIMURA T
    Can ultra-thin strut drug-eluting stents improve outcomes?
    Lancet. 2019 Feb 28. pii: S0140-6736(19)30286.
    PubMed     Text format    


  29. ZAMAN A, de Winter RJ, Kogame N, Chang CC, et al
    Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial.
    Lancet. 2019 Feb 28. pii: S0140-6736(18)32467.
    PubMed     Text format     Abstract available


  30. MEHRAN R, Vogel B, Ortega R, Cooney R, et al
    The Lancet Commission on women and cardiovascular disease: time for a shift in women's health.
    Lancet. 2019 Feb 8. pii: S0140-6736(19)30315.
    PubMed     Text format    


    December 2018
  31. NASLUND U, Ng N, Lundgren A, Fharm E, et al
    Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial.
    Lancet. 2018 Dec 3. pii: S0140-6736(18)32818.
    PubMed     Text format     Abstract available


    November 2018
  32. ZELNIKER TA, Wiviott SD, Raz I, Im K, et al
    SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Lancet. 2018 Nov 9. pii: S0140-6736(18)32590.
    PubMed     Text format     Abstract available


    October 2018
  33. COLOMBO A, Giannini F
    Encouraging data from ABSORB IV pave the way to new scaffolds.
    Lancet. 2018;392:1490-1491.
    PubMed     Text format    


  34. STONE GW, Ellis SG, Gori T, Metzger DC, et al
    Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.
    Lancet. 2018;392:1530-1540.
    PubMed     Text format     Abstract available


  35. WILLEIT P, Ridker PM, Nestel PJ, Simes J, et al
    Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
    Lancet. 2018 Oct 4. pii: S0140-6736(18)31652.
    PubMed     Text format     Abstract available


  36. MAFHAM M, Preiss D
    HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32348.
    PubMed     Text format    


  37. HERNANDEZ AF, Green JB, Janmohamed S, D'Agostino RB Sr, et al
    Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32261.
    PubMed     Text format     Abstract available


    September 2018
  38. CAMENZIND E, Popovic B
    Are all drug-eluting stents created equal?
    Lancet. 2018 Sep 21. pii: S0140-6736(18)32334.
    PubMed     Text format    


  39. VON BIRGELEN C, Zocca P, Buiten RA, Jessurun GAJ, et al
    Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, ran
    Lancet. 2018 Sep 21. pii: S0140-6736(18)32001.
    PubMed     Text format     Abstract available


  40. DEHGHAN M, Mente A, Rangarajan S, Sheridan P, et al
    Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study.
    Lancet. 2018 Sep 11. pii: S0140-6736(18)31812.
    PubMed     Text format     Abstract available


  41. HO HH, Ong PJL
    BASKET-SMALL 2: advancing DCB beyond in-stent restenosis.
    Lancet. 2018;392:802-804.
    PubMed     Text format    


  42. LANSKY A, Wijns W, Xu B, Kelbaek H, et al
    Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial.
    Lancet. 2018 Sep 3. pii: S0140-6736(18)31649.
    PubMed     Text format     Abstract available


  43. PILGRIM T, Piccolo R, Heg D, Roffi M, et al
    Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.
    Lancet. 2018;392:737-746.
    PubMed     Text format     Abstract available


    August 2018
  44. VRANCKX P, Valgimigli M, Juni P, Hamm C, et al
    Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, ope
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31858.
    PubMed     Text format     Abstract available


  45. CAPODANNO D, Angiolillo DJ
    Aspirin for primary prevention of cardiovascular disease.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31990.
    PubMed     Text format    


  46. GAZIANO JM, Brotons C, Coppolecchia R, Cricelli C, et al
    Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31924.
    PubMed     Text format     Abstract available


  47. VALGIMIGLI M, Frigoli E, Leonardi S, Vranckx P, et al
    Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31714.
    PubMed     Text format     Abstract available


  48. ANGIOLILLO DJ
    Vascular access and antithrombotic therapy in patients with acute coronary syndrome.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31921.
    PubMed     Text format    


  49. BLANKENBERG S, Neumann JT, Westermann D
    Diagnosing myocardial infarction: a highly sensitive issue.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31996.
    PubMed     Text format    


  50. JEGER RV, Farah A, Ohlow MA, Mangner N, et al
    Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31719.
    PubMed     Text format     Abstract available


  51. SHAH ASV, Anand A, Strachan FE, Ferry AV, et al
    High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31923.
    PubMed     Text format     Abstract available


  52. OIKONOMOU EK, Marwan M, Desai MY, Mancio J, et al
    Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31114.
    PubMed     Text format     Abstract available


  53. MAHABADI AA, Rassaf T
    Imaging of coronary inflammation for cardiovascular risk prediction.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31716.
    PubMed     Text format    


  54. MENTE A, O'Donnell M, Rangarajan S, McQueen M, et al
    Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study.
    Lancet. 2018;392:496-506.
    PubMed     Text format     Abstract available


  55. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.
    Lancet. 2018;392:477-486.
    PubMed     Text format     Abstract available


    July 2018
  56. THEKEN KN, Grosser T
    Weight-adjusted aspirin for cardiovascular prevention.
    Lancet. 2018 Jul 12. pii: S0140-6736(18)31307.
    PubMed     Text format    


  57. DOWLING C, Firoozi S, Brecker S
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:28.
    PubMed     Text format    


  58. FRANCIS DP, Al-Lamee R
    Percutaneous coronary intervention for stable angina in ORBITA - Authors' reply.
    Lancet. 2018;392:28-30.
    PubMed     Text format    


  59. BANNING A, Redwood S
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:28.
    PubMed     Text format    


  60. BAUER A, Rizas KD, Massberg S
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:27.
    PubMed     Text format    


  61. REED GW, Kapadia SR
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:27-28.
    PubMed     Text format    


  62. POCOCK SJ
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:26-27.
    PubMed     Text format    


  63. BARAKAT MF, Simitsis P
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:26.
    PubMed     Text format    


  64. TU T, Liu Q, Hu X, Zhou S, et al
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:25.
    PubMed     Text format    


  65. MUTHALALY RG, Nerlekar N, Brown AJ
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:25-26.
    PubMed     Text format    


  66. DEGRELL P, Picard F, Varenne O
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:25.
    PubMed     Text format    


    June 2018
  67. PATEL T, Tesfaldet B, Chowdhury I, Kettermann A, et al
    Endpoints in diabetes cardiovascular outcome trials.
    Lancet. 2018;391:2412.
    PubMed     Text format    


  68. MARIATHAS M, Curzen N
    Troponin assays: developing indications.
    Lancet. 2018;391:2398-2399.
    PubMed     Text format    


  69. DEVEREAUX PJ, Duceppe E, Guyatt G, Tandon V, et al
    Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
    Lancet. 2018;391:2325-2334.
    PubMed     Text format     Abstract available


  70. IKEMURA N, Sawano M, Ueda I, Fukuda K, et al
    Consequence of reimbursement policy alteration for urgent PCI in Japan.
    Lancet. 2018;391:2208-2209.
    PubMed     Text format    


    May 2018
  71. MONTAIGNE D, Coisne A, Marechal X, Lefebvre P, et al
    Daytime variations in perioperative myocardial injury - Authors' reply.
    Lancet. 2018;391:2106.
    PubMed     Text format    


  72. SPADACCIO C, Dalby M, Danton MHD
    Daytime variations in perioperative myocardial injury.
    Lancet. 2018;391:2105-2106.
    PubMed     Text format    


  73. LUCCHINETTI E, Zaugg M
    Daytime variations in perioperative myocardial injury.
    Lancet. 2018;391:2104-2105.
    PubMed     Text format    


  74. BARTMAN CM, Oyama Y, Eckle T
    Daytime variations in perioperative myocardial injury.
    Lancet. 2018;391:2104.
    PubMed     Text format    


  75. BRILAKIS ES, Edson R, Bhatt DL, Goldman S, et al
    Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial.
    Lancet. 2018 May 11. pii: S0140-6736(18)30801.
    PubMed     Text format     Abstract available


  76. PYLYPCHUK R, Wells S, Kerr A, Poppe K, et al
    Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study.
    Lancet. 2018 May 4. pii: S0140-6736(18)30664.
    PubMed     Text format     Abstract available


  77. DAMEN JAAG, Hooft L, Moons KGM
    Contemporary cardiovascular risk prediction.
    Lancet. 2018 May 4. pii: S0140-6736(18)30842.
    PubMed     Text format    


    April 2018
  78. DEHGHAN M, Mente A, Yusuf S
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple? - Authors' reply.
    Lancet. 2018;391:1681-1682.
    PubMed     Text format    


  79. HANSEL B, Roussel R, Giral P
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1680.
    PubMed     Text format    


  80. KLEBER ME, Delgado GE, Dawczynski C, Lorkowski S, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1680-1681.
    PubMed     Text format    


  81. CAO XP, Tan CC, Yu JT
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1679-1680.
    PubMed     Text format    


  82. CARBONE S, Billingsley H, Abbate A
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1679.
    PubMed     Text format    


  83. LORKOWSKI S, Richter M, Linseisen J, Watzl B, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1678-1679.
    PubMed     Text format    


  84. ROSSOUW JE, Prentice RL
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1677.
    PubMed     Text format    


  85. BHOPAL RS, Misra A
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1677-1678.
    PubMed     Text format    


  86. MANN J, Meerpohl J, Nishida C, McLean R, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1676.
    PubMed     Text format    


  87. REYNOLDS AN
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1676.
    PubMed     Text format    


  88. KAHLEOVA H, Crosby L, Levin S, Barnard ND, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1676-1677.
    PubMed     Text format    


  89. CHU DK, Kim LH, Young PJ, Zamiri N, et al
    Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis.
    Lancet. 2018;391:1693-1705.
    PubMed     Text format     Abstract available


    March 2018
  90. ALKHALIL M
    Bioresorbable polymer drug-eluting stents.
    Lancet. 2018;391:936.
    PubMed     Text format    


  91. KANDZARI DE, Mauri L, Koolen JJ, Doros G, et al
    Bioresorbable polymer drug-eluting stents - Authors' reply.
    Lancet. 2018;391:936-937.
    PubMed     Text format    


  92. SHAH R
    Bioresorbable polymer drug-eluting stents.
    Lancet. 2018;391:935-936.
    PubMed     Text format    


  93. MOTOVSKA Z, Bhatt DL
    12 months of DAPT after acute coronary syndrome still beats 6 months.
    Lancet. 2018 Mar 9. pii: S0140-6736(18)30612.
    PubMed     Text format    


  94. HAHN JY, Song YB, Oh JH, Cho DK, et al
    6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
    Lancet. 2018 Mar 9. pii: S0140-6736(18)30493.
    PubMed     Text format     Abstract available


    February 2018
  95. HEAD SJ, Milojevic M, Daemen J, Ahn JM, et al
    Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.
    Lancet. 2018 Feb 22. pii: S0140-6736(18)30423.
    PubMed     Text format     Abstract available


  96. BHATT DL
    CABG the clear choice for patients with diabetes and multivessel disease.
    Lancet. 2018 Feb 22. pii: S0140-6736(18)30424.
    PubMed     Text format    


  97. PAULES CI, Subbarao K
    Influenza vaccination and prevention of cardiovascular disease mortality - Authors' reply.
    Lancet. 2018;391:427-428.
    PubMed     Text format    


  98. CALDEIRA D, Ferreira JJ, Costa J
    Influenza vaccination and prevention of cardiovascular disease mortality.
    Lancet. 2018;391:426-427.
    PubMed     Text format    


    January 2018
  99. JOBS A, Desch S, Thiele H
    Great expectations - Authors' reply.
    Lancet. 2018;391:306-307.
    PubMed     Text format    


  100. LEMESLE G, Laine M, Pankert M, Puymirat E, et al
    Great expectations.
    Lancet. 2018;391:306.
    PubMed     Text format    


  101. ANAND SS, Bosch J, Eikelboom JW, Connolly SJ, et al
    Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet. 2018;391:219-229.
    PubMed     Text format     Abstract available


  102. BOCHATON T, Ovize M
    Circadian rhythm and ischaemia-reperfusion injury.
    Lancet. 2018;391:8-9.
    PubMed     Text format    


  103. BROWN DL, Redberg RF
    Last nail in the coffin for PCI in stable angina?
    Lancet. 2018;391:3-4.
    PubMed     Text format    


  104. GERBER RT, Gershlick AH
    A SENIOR moment? Bare-metal stents in elderly patients.
    Lancet. 2018;391:4-6.
    PubMed     Text format    


    December 2017
  105. SCHUMACHER H, Mahfoud F, Bohm M
    Overestimation of cardiovascular outcome incidence - Authors' reply.
    Lancet. 2017;390:2547.
    PubMed     Text format    


  106. YE Y, Fonseca R
    Overestimation of cardiovascular outcome incidence.
    Lancet. 2017;390:2546-2547.
    PubMed     Text format    


  107. THURSTON GD, Newman JD
    Walking to a pathway for cardiovascular effects of air pollution.
    Lancet. 2017 Dec 5. pii: S0140-6736(17)33078.
    PubMed     Text format    


  108. SINHARAY R, Gong J, Barratt B, Ohman-Strickland P, et al
    Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, cr
    Lancet. 2017 Dec 5. pii: S0140-6736(17)32643.
    PubMed     Text format     Abstract available


  109. DE WINTER RJ, Katagiri Y, Asano T, Milewski KP, et al
    A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 tri
    Lancet. 2017 Dec 1. pii: S0140-6736(17)33103.
    PubMed     Text format     Abstract available


    November 2017
  110. RIDKER PM, MacFadyen JG, Everett BM, Libby P, et al
    Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
    Lancet. 2017 Nov 13. pii: S0140-6736(17)32814.
    PubMed     Text format     Abstract available


  111. CONNOLLY SJ, Eikelboom JW, Bosch J, Dagenais G, et al
    Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet. 2017 Nov 10. pii: S0140-6736(17)32458.
    PubMed     Text format     Abstract available


  112. PRABHAKARAN D, Anand S, Watkins D, Gaziano T, et al
    Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition.
    Lancet. 2017 Nov 3. pii: S0140-6736(17)32471.
    PubMed     Text format     Abstract available


  113. AL-LAMEE R, Thompson D, Dehbi HM, Sen S, et al
    Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
    Lancet. 2017 Nov 1. pii: S0140-6736(17)32714.
    PubMed     Text format     Abstract available


    October 2017
  114. VARENNE O, Cook S, Sideris G, Kedev S, et al
    Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial.
    Lancet. 2017 Oct 31. pii: S0140-6736(17)32713.
    PubMed     Text format     Abstract available


  115. MONTAIGNE D, Marechal X, Modine T, Coisne A, et al
    Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbalpha antagonism: a single-centre propensity-matched cohort study and a randomised study.
    Lancet. 2017 Oct 26. pii: S0140-6736(17)32132.
    PubMed     Text format     Abstract available


  116. BYRNE RA, Schuster T
    Biodegradable polymer drug-eluting stents: caveat emptor.
    Lancet. 2017;390:1814-1816.
    PubMed     Text format    


    September 2017
  117. LEAR SA, Hu W, Rangarajan S, Gasevic D, et al
    The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study.
    Lancet. 2017 Sep 21. pii: S0140-6736(17)31634.
    PubMed     Text format     Abstract available


    August 2017
  118. SIBBING D, Aradi D, Jacobshagen C, Gross L, et al
    Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32155.
    PubMed     Text format     Abstract available


  119. RIDKER PM, MacFadyen JG, Thuren T, Everett BM, et al
    Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32247.
    PubMed     Text format     Abstract available


  120. JINATONGTHAI P, Kongwatcharapong J, Foo CY, Phrommintikul A, et al
    Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis.
    Lancet. 2017;390:747-759.
    PubMed     Text format     Abstract available


    April 2017
  121. SHAH R
    Optical coherence tomography-guided PCI.
    Lancet. 2017;389:1607.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Ischemic Heart Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: